Background
Phase 3 randomized open-label trial evaluating subcutaneous daratumumab added to bortezomib/cyclophosphamide/dexamethasone (D-VCd) versus VCd alone in 388 patients with newly diagnosed light-chain (AL) amyloidosis. VCd was the prior standard of care. This is the preplanned final analysis after the primary analysis established D-VCd as the first approved therapy for AL amyloidosis based on hematologic complete response.
Interventions and follow up
Arm A: Six cycles of VCd + subcutaneous daratumumab, followed by single-agent daratumumab every 4 weeks for up to 24 total cycles
Arm B: Six cycles of VCd alone (control)
Primary endpoint: Hematologic complete response (CR)
mFollow up: 61.4 months
Arm B: Six cycles of VCd alone (control)
Primary endpoint: Hematologic complete response (CR)
mFollow up: 61.4 months
Results
Hematologic CR: 59.5% with D-VCd vs 19.2% with VCd (OR 6.03; 95% CI 3.80–9.58; P<.0001)
Median time to hematologic CR: 67.5 days (range 8.0–879.0) with D-VCd vs 85.0 days (range 14.0–617.0) with VCd
Major organ deterioration PFS (MOD-PFS): HR 0.44 (95% CI 0.31–0.63; P<.0001) favoring D-VCd
Overall survival: HR 0.62 (95% CI 0.42–0.90; P=.0121) favoring D-VCd
Cardiac and renal response rates: 2–3 times higher with D-VCd vs VCd (exact percentages NR in abstract)
Median time to hematologic CR: 67.5 days (range 8.0–879.0) with D-VCd vs 85.0 days (range 14.0–617.0) with VCd
Major organ deterioration PFS (MOD-PFS): HR 0.44 (95% CI 0.31–0.63; P<.0001) favoring D-VCd
Overall survival: HR 0.62 (95% CI 0.42–0.90; P=.0121) favoring D-VCd
Cardiac and renal response rates: 2–3 times higher with D-VCd vs VCd (exact percentages NR in abstract)
Adverse events
Overall profile: Safety was consistent with the known profiles of VCd and daratumumab; no new safety signals identified
Detailed rates: Grade-specific rates, discontinuation rates, and treatment-related deaths NR in abstract
Detailed rates: Grade-specific rates, discontinuation rates, and treatment-related deaths NR in abstract
Conclusions
Adding subcutaneous daratumumab to VCd produced deeper and faster hematologic responses, improved organ-function recovery, and translated into statistically significant improvements in both overall survival and major organ deterioration-progression-free survival in newly diagnosed AL amyloidosis. Achieving hematologic or cardiac CR was associated with improved MOD-PFS and OS.
Key Limitations
Open-label design; crossover after the primary analysis may have attenuated the OS difference; safety details summarized rather than tabulated in the abstract; conducted predominantly in patients eligible for bortezomib-based therapy (excluding Mayo stage IIIB cardiac AL amyloidosis at entry).
Clinical Context
Confirms D-VCd as the standard-of-care frontline regimen for newly diagnosed AL amyloidosis. The final analysis adds definitive OS benefit to the previously demonstrated CR and MOD-PFS advantages that supported regulatory approval (FDA approval of subcutaneous daratumumab + VCd for AL amyloidosis in January 2021). Reinforces ANDROMEDA-based D-VCd as the global reference regimen and the comparator for next-generation AL amyloidosis trials (e.g., CAEL-101, anti-fibril mAbs, BCMA-directed approaches).